Full Text
EE311 Cost-Effectiveness Analysis of Ruxolitinib vs Best Available Therapy for the Treatment of Myelofibrosis in the United States

Abstract

Authors

A Smith BC Martin

Back to Volume 25, Supplemental Issue 7S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×